Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

MRNA dominated the tape, ranging from $59.29 to $176.66 (+197.96%) and closing at $145.55, or 73.49% of its range, with a +140.26% period return. Its 370.49% realized volatility against 61.40% implied produced a 21.78x realized/implied ratio — by far the period's largest volatility mispricing. Other outsized underpricings clustered in mid-cap biotech and services: TEM (7.17x), HIMS (4.61x), BNTX (4.52x) and MRK (4.52x), where a modest 24.54% implied read against 44.61% realized.

The opposite pattern held in the highest-implied names. CDXS (374.22% implied, 0.31x), KPTI (0.49x), DBVT (0.53x) and STIM (0.59x) all realized far less than priced — and all four finished lower, with STIM the top decliner at -22.38%.

Range positioning split cleanly. GILD closed nearest its high at 92.00%, joined by MGNX (86.52%), EBS (81.98%) and JNJ (77.07%). At the other end, SYK settled at just 1.45% of range, with HIMS (4.95%), LLY (7.24%), QURE (7.80%) and ABT (9.62%) also finishing near lows.

Broader Market Context

Differential behavior within the sector. The dispersion here is striking for a single sector: roughly 220 percentage points separated MRNA (+197.96%) from STIM (-22.38%). Large-cap pharma and managed care behaved like the defensive assets they are usually treated as — JNJ (+10.11%), GILD (+14.44%), ABBV (+8.73%), BMY (+8.95%) and MRK (+21.73%) all advanced with realized volatility in the low-to-mid 20s, and most closed in the upper half of their ranges. Small-cap biotech and device names went the other way, with CDXS, KPTI, STIM, DBVT and QURE all down double digits despite triple-digit implied vols. Notably, MedTech was the sector's weak spot: SYK (-12.94%) and ABT (-8.51%) both closed near their lows, diverging sharply from pharma.

Rotation versus idiosyncratic moves. The broad, low-volatility strength across XLV (+6.54%), the big pharma complex, and managed care (HUM +11.64%, ELV +7.97%, CNC +8.53%, CVS +6.66%) is consistent with a defensive rotation into Health Sector exposure — steady, correlated gains rather than one-off spikes. Layered on top are clearly idiosyncratic moves that rotation cannot explain:

• MRNA's 21.78x realized/implied gap looks stock-specific, not sector beta.
• TEM (+47.84%), BNTX (+32.84%) and EBS (+50.68%) showed similar single-name signatures.
• LLY's -12.00% and SYK's near-low close ran opposite the sector's defensive tone.

Plausible current-event backdrop. Several themes could plausibly relate to this pattern, though none is confirmed by the data. The managed-care cohort moving together is consistent with sensitivity to reimbursement, utilization-trend or policy headlines that affect payers as a group. Large-cap pharma strength may reflect the sector's typical bid during risk-off or rate-uncertainty periods, when durable cash flows are favored. The violent, one-sided moves in vaccine-adjacent and clinical-stage names are consistent with binary catalysts — trial readouts, regulatory decisions or approval timelines — while the elevated implied vols in CDXS, KPTI and DBVT that failed to realize suggest the market was hedging catalysts that either passed quietly or slipped. Weakness in MedTech alongside pharma strength may point to procedure-volume or capital-spending concerns rather than sector-wide risk aversion.